Contrasting Anixa Biosciences (NASDAQ:ANIX) & Eterna Therapeutics (NASDAQ:ERNA)

Eterna Therapeutics (NASDAQ:ERNA) and Anixa Biosciences (NASDAQ:ANIX) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their risk, dividends, earnings, profitability, valuation, institutional ownership and analyst recommendations.

Profitability

This table compares Eterna Therapeutics and Anixa Biosciences’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Eterna Therapeutics	-7,513.88%	N/A	-117.48%
Anixa Biosciences	N/A	-58.55%	-53.29%

Valuation & Earnings

This table compares Eterna Therapeutics and Anixa Biosciences”s revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Eterna Therapeutics	$70,000.00	26.28	-$21.67 million	($8.31)	-0.04
Anixa Biosciences	$210,000.00	489.13	-$12.55 million	($0.39)	-8.18

Anixa Biosciences has higher revenue and earnings than Eterna Therapeutics. Anixa Biosciences is trading at a lower price-to-earnings ratio than Eterna Therapeutics, indicating that it is currently the more affordable of the two stocks.

Insider & Institutional Ownership

70.6% of Eterna Therapeutics shares are owned by institutional investors. Comparatively, 29.1% of Anixa Biosciences shares are owned by institutional investors. 4.5% of Eterna Therapeutics shares are owned by insiders. Comparatively, 22.6% of Anixa Biosciences shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Analyst Recommendations

This is a breakdown of current ratings and recommmendations for Eterna Therapeutics and Anixa Biosciences, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Eterna Therapeutics	0	0	0	0	0.00
Anixa Biosciences	0	0	2	1	3.33

Anixa Biosciences has a consensus price target of $8.50, suggesting a potential upside of 166.46%. Given Anixa Biosciences’ stronger consensus rating and higher possible upside, analysts clearly believe Anixa Biosciences is more favorable than Eterna Therapeutics.

Volatility & Risk

Eterna Therapeutics has a beta of 4.29, suggesting that its share price is 329% more volatile than the S&P 500. Comparatively, Anixa Biosciences has a beta of 0.93, suggesting that its share price is 7% less volatile than the S&P 500.

Summary

Anixa Biosciences beats Eterna Therapeutics on 11 of the 15 factors compared between the two stocks.

About Eterna Therapeutics

Eterna Therapeutics Inc., a life science company, provides mRNA cell engineering technologies. Its technologies include mRNA cell reprogramming and gene editing; NoveSlice and UltraSlice gene-editing proteins; and the ToRNAdo mRNA delivery system. The company has a license agreement with Factor Bioscience Limited. Eterna Therapeutics Inc. was founded in 2018 and is based in Cambridge, Massachusetts.

About Anixa Biosciences

Anixa Biosciences, Inc., a biotechnology company, develops therapies and vaccines focusing on critical unmet needs in oncology and infectious diseases. The company's therapeutics programs include the development of a chimeric endocrine receptor T-cell therapy, a novel form of chimeric antigen receptor T-cell (CAR-T) technology focusing on the treatment of ovarian cancer. Its vaccine programs comprise the development of a vaccine against triple negative breast cancer; and a preventative vaccine against ovarian cancer. The company is also developing immuno-therapy drugs against cancer. The company was formerly known as ITUS Corporation and changed its name to Anixa Biosciences, Inc. in October 2018. Anixa Biosciences, Inc. was incorporated in 1982 and is based in San Jose, California.